Guardant Health Expands Shield Blood Test Coverage Through Carelon

MT newswire2026/09/01 13:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:03 AM EDT, 09/01/2026 (MT Newswires) -- Guardant Health's (GH) Shield blood test for colorectal cancer screening will be covered under Carelon Healthcare Services' clinical guidelines effective Nov. 15, the company said Tuesday. The coverage expansion will increase the number of people with commercial coverage for Shield to about 90 million, or 75% of eligible US patients, the company said. Shield is a blood test approved by the US Food and Drug Administration for primary colorectal cancer screening in average-risk adults aged 45 years and older, offering a more accessible screening option through a routine blood draw, it added.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41